TAIAN CITY, Shandong, China /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) (the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on July 8, 2008, the Company was awarded the Advanced Technology Certification for Foreign Funded Enterprises (the "Certification") from the Department of Foreign Trade and Economic Cooperation of Shandong Province ("Shandong DOFTEC").
Shandong DOFTEC is a government-sponsored organization in charge of foreign trade affairs and economic cooperation for Shandong Province. The Certification was granted to the Company because the Company met the strict requirements and standards set by Shandong DOFTEC for high-tech foreign-funded companies.
"It is an honor to receive the Certification," said Mr. Chao Ming Zhao, the Company's CEO. "We believe that the recognition from Shandong DOFTEC enhances our competitive position and confirms our commitment to the production of high-quality plasma-based products with advanced technology."
The Certification is renewable in three years, subject to the Company's continued adherence to Shandong DOFTEC's Certification standards.
About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume, and its immunoglobulin products are used for the treatment and prevention of diseases.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating
to the business of China Biologic Products, Inc., and its subsidiary
companies. All statements, other than s
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved